Browse all articles in the Therapy Context category.
Atezolizumab (Tecentriq) is a PD-L1–blocking immunotherapy used across several cancers. This guide translates the major clinical trials and side-effect data into clear, practical takeaways.
Daratumumab is the first anti-CD38 antibody to reshape multiple myeloma care. Here’s what it does, where it shines, safety must-knows, and the strongest trial data—made simple.
Excerpt: Ocrelizumab, a B-cell–targeting antibody, is one of the most effective MS therapies. Here’s what rigorous trials and long-term studies say about benefits, risks, vaccines, pregnancy, and real-world use.
Mepolizumab, a targeted anti-IL-5 antibody, can cut exacerbations and steroid use in eosinophilic disease. Here’s the best evidence—decoded and demystified.